GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

What Are Adipose-Derived Stem Cells?

Adipose-derived stem cells (ADSCs) are adult stromal/stem cells obtained from adipose, or fat, tissue. They are not mature fat cells. Researchers can grow them in culture and, under laboratory conditions, guide them to form fat, bone, and cartilage cell types.107632701300062859J.jcyt.2013.02.006

ADSCs are one component of the stromal vascular fraction (SVF), a mixture of cells isolated from fat. Fresh SVF, cultured ADSCs, whole-fat grafts, and cell-free products are not interchangeable. In particular, a cell-free extract contains no living stem cells. Laboratory findings do not establish that an ADSC treatment will repair tissue in a person.

What Are Adipose-Derived Stem Cells?

Where ADSCs come from

In 2001, Zuk and colleagues described a cell population from human liposuction tissue that could develop into several cell types in culture. This was laboratory research, not evidence of treatment success in patients.107632701300062859

Fat tissue contains mature fat cells, blood vessels, immune cells, and supporting tissue. Separating out mature fat cells leaves a mixed cellular fraction: SVF. It contains stromal cells alongside vessel-lining cells, immune cells, and other populations; it is not purified ADSCs.J.jcyt.2013.02.006 Research on cells surrounding small blood vessels helped explain the relationship between perivascular cells and mesenchymal stromal cells (MSCs), including those obtained from fat.J.stem.2008.07.003

How researchers identify ADSCs

No single surface marker identifies an ADSC. The IFATS/ISCT joint statement describes an uncultured stromal population within SVF as CD45−, CD235a−, CD31−, and CD34+. The minus signs indicate absent markers; the plus sign indicates a present marker. This profile excludes common blood and vessel-lining populations while identifying a stromal subset—not the composition of the entire SVF sample.J.jcyt.2013.02.006

After culture expansion, ASCs typically express CD73, CD90, and CD105 and lack CD45 and CD31. CD36 positivity and CD106 negativity help distinguish them from bone marrow MSCs.J.jcyt.2013.02.006 The International Society for Cellular Therapy’s minimum MSC criteria combine plastic adherence, a specified marker profile, and the ability to differentiate into fat, bone, and cartilage in vitro. Markers alone are insufficient.14653240600855905 Clonal studies also support the presence of multipotent cells in human adipose tissue.Mbc.e02 02 0105

ASC commonly means adipose-derived stromal/stem cell; ADSC is another widely used abbreviation. Neither abbreviation makes whole fat, mixed SVF, or a cell-free extract the same product as cultured cells. Nor does meeting laboratory criteria prove clinical effectiveness.J.jcyt.2013.02.006J.stem.2018.05.004

Preparation What it contains Important distinction
Fresh SVF A mixture of stromal, vascular, immune, and other cells Contains a stromal subset; not a pure ADSC preparation
Culture-expanded ADSCs/ASCs Cells selected and multiplied in culture Identity requires laboratory characterization, not just a cell count
Whole-fat graft Fat cells, supporting tissue, and associated cells A tissue graft, not a defined dose of isolated ADSCs
Cell-free extract or conditioned medium Material collected from cells or their culture medium, without living cells Not a living-cell treatment; cell-therapy trial results cannot be assumed to apply

How ADSCs are collected and processed

Fat can be collected by liposuction. Processing separates a cell-containing fraction, and culture expansion can then increase the number of stromal cells. Protocols differ: freshly isolated SVF and culture-expanded cells are different preparations, with different identity and quality-control requirements.J.jcyt.2013.02.006

For example, the knee trial discussed below used autologous SVF prepared and injected during the same clinical visit.0363546519899923 The Crohn’s trial used a single local administration of 120 million culture-expanded allogeneic cells.S0140 6736(16)31203 X These are not equivalent interventions merely because both originate from fat.

Autologous cells come from the person being treated. Allogeneic cells come from a screened donor. Ask whose cells will be used, how they are processed, and how identity, sterility, viability, and potency are assessed. “Autologous” identifies the source; it is not a safety certificate.

What ADSCs may do

Scientists study both differentiation and the signals that MSCs release, including effects on immune activity and tissue responses. How these mechanisms contribute to patient outcomes depends on the product and clinical setting. Promising laboratory or animal findings have not consistently translated into benefits in larger human trials.J.stem.2018.05.004

Growing cartilage-like tissue in a dish is therefore a different claim from regenerating cartilage in a knee. In the 39-person SVF trial below, symptoms improved but MRI did not show increased cartilage thickness.0363546519899923

ADSCs versus bone marrow MSCs

Both can share core MSC markers and laboratory differentiation properties, but their tissue sources and some marker patterns differ.J.jcyt.2013.02.00614653240600855905 Fat is collected from adipose tissue; bone marrow MSCs come from marrow. A shared “MSC” label does not establish equal potency, safety, or effectiveness. Evidence should match the tissue source, manufacturing process, dose, route, and condition being treated.J.stem.2018.05.004

What human studies show

Studies in knee osteoarthritis and Crohn’s fistulas illustrate why the exact preparation matters. One tested mixed SVF; the other tested expanded donor-derived cells. Neither establishes the effectiveness of a cell-free extract.

Knee osteoarthritis

Garza and colleagues randomized 39 adults with symptomatic knee osteoarthritis to high-dose SVF, low-dose SVF, or placebo in a US multisite, double-blind trial. The cells were injected into the knee joint. At six months, median improvement from baseline in WOMAC, a pain and function score, was 83.9%, 51.5%, and 25.0%, respectively. At 12 months, the corresponding figures were 89.5%, 68.2%, and 0%. These are changes in a score—not percentages of patients cured.0363546519899923

MRI showed no change in cartilage thickness, and no serious adverse events were reported. This small study supports a symptom benefit with the tested SVF preparation over one year; it does not establish cartilage regrowth, long-term safety, or equivalent results with another preparation.0363546519899923 Its registration, NCT02726945, identifies the protocol and intervention; registration itself does not demonstrate efficacy.NCT02726945

Crohn’s perianal fistulas

The phase 3 ADMIRE-CD trial randomized 212 adults with treatment-refractory complex perianal fistulas in Crohn’s disease. Patients received a single local injection of 120 million expanded allogeneic adipose-derived cells, darvadstrocel, or placebo, alongside standard care. In the modified intention-to-treat analysis, combined remission at 24 weeks was 51.5% versus 35.6%. Treatment-related adverse events occurred in 17% versus 29%; anal abscess and proctalgia were the most common.S0140 6736(16)31203 XJ.gastro.2017.12.020

Combined remission meant closure of the treated draining external openings and no fluid collections larger than 2 cm on MRI. At 52 weeks, the rates were 56.3% with cells and 38.6% with placebo. This was fistula remission, not a cure for Crohn’s disease.J.gastro.2017.12.020

A separate phase 3 confirmatory trial, ADMIRE CD II, randomized 568 adults across Europe, Israel, and North America. Both groups underwent fistula curettage and closure of the internal opening. At 24 weeks, combined remission was 48.8% with darvadstrocel and 46.3% with placebo, without a statistically significant difference (P = .571). Treatment-emergent adverse events occurred in 73.0% and 73.4% of the safety populations, respectively; no new safety signals were identified.J.gastro.2025.12.033

Alofisel, the darvadstrocel product authorized in the EU in 2018, had its EU authorization withdrawn on December 13, 2024, at the holder’s request. EMA explained that available evidence was insufficient to confirm its benefit after the larger trial failed to show superiority over placebo.Alofisel withdrawn eu market The differing trial results do not establish a single explanation for the discrepancy or a conclusion about all ADSC preparations.

A specific approved sheet product

Japan approved Allostem Sheet (nivadstrocel) on April 3, 2026. It is a sheet made from cultured mesenchymal stem cells derived from healthy adult donors’ subcutaneous fat. It is applied to intractable or recurrent erosions or ulcers in specified forms of epidermolysis bullosa: dystrophic EB, junctional EB, and severe generalized EB simplex. This is a defined wound-treatment indication, not approval of ADSC injections for arthritis, aging, or cosmetic use.000283257.pdf

Risks and safety limits

Risks depend on collection, processing, delivery, and the patient’s condition. Harvesting and injection can cause pain, bleeding, or infection; anesthesia adds its own risks. Processing also creates opportunities for contamination. Using a person’s own cells does not remove these hazards.

FDA reports blindness, tumor formation, and serious infections among adverse outcomes associated with unapproved regenerative products, a broad category that includes fat-derived SVF. These reports are not an incidence estimate for every ADSC product, but they show why unapproved care should not be assumed safe. FDA oversight of a trial is not the same as FDA conducting the trial.Important patient and consumer information about regenerative medicine therapies

A 2021 meta-analysis pooled 62 randomized MSC trials with 3,546 participants across multiple diseases and cell preparations. It did not identify an increased risk of serious outcomes such as death or infection, but it found more transient fever and several other adverse events, including administration-site reactions. Its broad MSC findings cannot establish the safety of a particular ADSC preparation or exclude rare or delayed harm.S13287 021 02609 x

Approval, research, or clinic service?

Category What to verify What it does not establish
Approved product The regulator’s listing, exact product, indication, and current status Approval for other diseases, preparations, or routes
Clinical trial The protocol, sponsor, relevant regulatory oversight, consent, and reporting arrangements That registration proves efficacy or authorizes general marketing
Clinic service under Japan’s ASRM framework The submitted provision plan, committee review, and applicable requirements Product marketing approval or proof of clinical benefit

United States: FDA’s warning distinguishes approval for marketing from investigational use under an FDA-overseen Investigational New Drug (IND) framework. An IND is not marketing approval, and a ClinicalTrials.gov entry alone does not prove compliance.Important patient and consumer information about regenerative medicine therapies FDA’s approved cellular and gene therapy list, dated September 17, 2026, does not list an adipose-derived stem cell product for knee osteoarthritis or cosmetic use.Approved cellular and gene therapy products

Japan: The Act on the Safety of Regenerative Medicine (ASRM) provides a framework for regenerative care, including provision-plan submission and certified-committee review, with requirements depending on the risk category. Amendments took effect in May 2025. This framework is distinct from product marketing authorization.Index A clinic plan number should be checked against the actual proposed procedure, not presented as proof that it works. PMDA’s product list through July 2026 includes Allostem Sheet’s specified EB indication, not an injectable SVF product for knee osteoarthritis.000283257.pdf

European Union: Alofisel’s former authorization is historical, not a current EU treatment approval. EMA states that no new patients should receive it after December 13, 2024.Alofisel withdrawn eu market

Checking a treatment offer

A concrete document check is to compare the offer with the study being cited. If an offer for cultured ADSCs cites NCT02726945, the registry describes autologous SVF, not cultured ADSCs. That mismatch matters even when both preparations originate from fat.NCT02726945 This comparison tests whether the evidence matches the proposed procedure; it does not predict your outcome.

Likewise, a headline saying “89.5% improvement” should lead you to ask what improved. In the knee trial, it was the median change in a symptom score in a small group, not an 89.5% cure rate or demonstrated cartilage regrowth.0363546519899923

Before paying, ask for written answers:

  1. What is the exact preparation: whole fat, fresh SVF, cultured cells, or a cell-free product?
  2. Whose cells are used, how many are viable, and what identity, sterility, and potency tests are performed?
  3. Which human study matches my condition, cell preparation, dose, and delivery route?
  4. Is this an approved product, a regulated trial, or a clinic service? Which document demonstrates that status?
  5. What are the alternatives, expected uncertainties, specific risks, and arrangements for complications?
  6. What is the full cost, including collection, processing, follow-up, and any repeat procedures?
  7. Which outcomes will be measured, for how long, and will the clinic share adverse-event as well as outcome data?

A testimonial cannot replace a controlled study, and a submitted plan cannot replace a product approval. If a clinic uses either as proof of effectiveness, ask for the underlying evidence rather than relying on the label “stem cells.”

Considering regenerative care in Japan?

If you are weighing your options, you can contact our team with general questions about the treatment process, eligibility screening, and next steps. We share information only; every medical decision stays with you and your physician.

Contact Us

Bottom line

ADSCs are adult stromal/stem cells obtained from fat—not fat cells, whole SVF, or a cell-free extract. Their laboratory properties explain scientific interest, but patient benefit depends on the exact preparation and indication. The knee trial enrolled only 39 people and did not show cartilage regrowth; the larger darvadstrocel confirmatory trial did not meet its primary endpoint.0363546519899923J.gastro.2025.12.033 Ask for evidence that matches the treatment being offered.

Discuss knee osteoarthritis options with an orthopedic surgeon or rheumatologist, and Crohn’s fistula care with a gastroenterologist or colorectal surgeon. This information is educational and does not replace individual medical advice.

Sources

  1. Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Engineering. 2001. https://doi.org/10.1089/107632701300062859 Accessed October 23, 2026.
  2. Bourin P, Bunnell BA, Casteilla L, et al. Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of IFATS and ISCT. Cytotherapy. 2013. https://doi.org/10.1016/j.jcyt.2013.02.006 Accessed October 27, 2026.
  3. Crisan M, Yap S, Casteilla L, et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell. 2008. https://doi.org/10.1016/j.stem.2008.07.003 Accessed October 23, 2026.
  4. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells: the International Society for Cellular Therapy position statement. Cytotherapy. 2006. https://doi.org/10.1080/14653240600855905 Accessed October 23, 2026.
  5. Zuk PA, Zhu M, Ashjian P, et al. Human adipose tissue is a source of multipotent stem cells. Molecular Biology of the Cell. 2002. https://doi.org/10.1091/mbc.e02-02-0105 Accessed October 23, 2026.
  6. Galipeau J, Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018. https://doi.org/10.1016/j.stem.2018.05.004 Accessed October 23, 2026.
  7. Garza JR, Campbell RE, Tjoumakaris FP, et al. Clinical efficacy of intra-articular mesenchymal stromal cells for the treatment of knee osteoarthritis: a double-blinded prospective randomized controlled clinical trial. The American Journal of Sports Medicine. 2020. https://doi.org/10.1177/0363546519899923 Accessed October 27, 2026.
  8. Panés J, García-Olmo D, Van Assche G, et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: a phase 3 randomised, double-blind controlled trial. The Lancet. 2016. https://doi.org/10.1016/S0140-6736(16)31203-X Accessed October 27, 2026.
  9. ClinicalTrials.gov. Adipose-derived SVF for the Treatment of Knee OA (NCT02726945). https://clinicaltrials.gov/study/NCT02726945 Accessed October 27, 2026.
  10. Panés J, García-Olmo D, Van Assche G, et al. Long-term efficacy and safety of stem cell therapy (Cx601) for complex perianal fistulas in patients with Crohn’s disease. Gastroenterology. 2018. https://doi.org/10.1053/j.gastro.2017.12.020 Accessed October 27, 2026.
  11. Colombel JF, Garcia Olmo D, Chen ST, et al. Darvadstrocel in patients with Crohn’s disease with complex perianal fistulas: the ADMIRE CD II phase 3 randomized trial. Gastroenterology. 2026. https://doi.org/10.1053/j.gastro.2025.12.033 Accessed October 27, 2026.
  12. European Medicines Agency. Alofisel withdrawn from the EU market (December 13, 2024); Alofisel EPAR withdrawal record. https://www.ema.europa.eu/en/news/alofisel-withdrawn-eu-market Accessed October 27, 2026.
  13. Pharmaceuticals and Medical Devices Agency (Japan). List of approved regenerative medical products, April 2015–July 2026; Allostem Sheet entry, approved April 3, 2026. https://www.pmda.go.jp/files/000283257.pdf Accessed October 27, 2026.
  14. US Food and Drug Administration. Important patient and consumer information about regenerative medicine therapies. Content current as of April 8, 2024. https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies Accessed October 27, 2026.
  15. Wang Y, Yi H, Song Y. The safety of MSC therapy over the past 15 years: a meta-analysis. Stem Cell Research & Therapy. 2021. https://doi.org/10.1186/s13287-021-02609-x Accessed October 27, 2026.
  16. US Food and Drug Administration. Approved cellular and gene therapy products. Content current as of September 17, 2026. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products Accessed October 27, 2026.
  17. Ministry of Health, Labour and Welfare (Japan). Regenerative and cell medicine and gene therapy: Act on the Safety of Regenerative Medicine. Accessed October 23, 2026. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/iryou/saisei_iryou/index.html Accessed October 27, 2026.